Trial Profile
A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in addition to carboplatin based chemotherapy (gemcitabine or paclitaxel)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Gemcitabine; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms ABIGAIL
- Sponsors Roche
- 21 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 06 May 2014 Results published in the Journal of Thoracic Oncology.
- 30 Sep 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.